User profiles for Isabelle Laverdière

Isabelle Laverdière

Associate professor, Faculty of pharmacy, Université Laval - Centre de Recherche du CHU …
Verified email at crchudequebec.ulaval.ca
Cited by 595

[HTML][HTML] Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia

I Laverdière, M Boileau, AL Neumann, H Frison… - Blood cancer …, 2018 - nature.com
Therapy for acute myeloid leukemia (AML) involves intense cytotoxic treatment and yet
approximately 70% of AML are refractory to initial therapy or eventually relapse. This is at least …

Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression

…, L Lacombe, BY Bao, Y Fradet, I Laverdiere… - Clinical Cancer …, 2013 - AACR
Purpose: Prostate cancer is a heterogeneous genetic disease, and molecular methods for
predicting prognosis in patients with aggressive form of the disease are urgently needed to …

[HTML][HTML] Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion

…, A Bergeron, Y Fradet, L Lacombe, I Laverdière… - Molecular …, 2022 - Elsevier
Objective The prostate is metabolically unique: it produces high levels of citrate for secretion
via a truncated tricarboxylic acid (TCA) cycle to maintain male fertility. In prostate cancer (…

[HTML][HTML] Human organ-specific 3D cancer models produced by the stromal self-assembly method of tissue engineering for the study of solid tumors

…, L Piquet, J Fradette, I Laverdiere… - BioMed Research …, 2020 - hindawi.com
Cancer research has considerably progressed with the improvement of in vitro study models,
helping to understand the key role of the tumor microenvironment in cancer development …

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients

…, D Jonker, F Couture, I Laverdière… - Pharmacogenetics …, 2015 - journals.lww.com
Objective Irinotecan is a cytotoxic agent used widely for the treatment of solid tumors, particularly
for metastatic colorectal cancers. Treatment with this drug frequently results in severe …

Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer

…, IC Chung, LC Chen, I Laverdiere… - … Journal of Cancer, 2014 - Wiley Online Library
Recent evidence indicates that microRNAs might participate in prostate cancer initiation,
progression and treatment response. Germline variations in microRNAs might alter target gene …

Are pharmacists from the province of Quebec ready to integrate pharmacogenetics into their practice

C Petit, A Croisetière, F Chen, I Laverdière - Pharmacogenomics, 2020 - Future Medicine
Aim: The pharmacists are identified as one of the best positioned health professionals to lead
intercollaborative efforts in tailoring medication based on pharmacogenetic information. As …

Untargeted metabolomics identifies metabolic dysregulation of sphingolipids associated with aggressive chronic lymphocytic leukaemia and poor survival

…, T Le, R Sergerie, I Laverdière… - Clinical and …, 2023 - Wiley Online Library
Background Metabolic dependencies of chronic lymphocytic leukaemia (CLL) cells may
represent new personalized treatment approaches in patients harbouring unfavourable features…

Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway

E Levesque, I Laverdiere, E Audet-Walsh, P Caron… - Clinical Cancer …, 2014 - AACR
Purpose: Reliable biomarkers that predict prostate cancer outcomes are urgently needed to
improve and personalize treatment approaches. With this goal in mind, we individually and …

[HTML][HTML] A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome

…, F Courtier, F Nguyen Van Long, I Laverdière… - Cells, 2023 - mdpi.com
In chronic lymphocytic leukemia (CLL), an elevated glycosyltransferase UGT2B17 expression
(UGT2B17 HI ) identifies a subgroup of patients with shorter survival and poor drug …